Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction, increasing peripheral vascular resistance and blood pressure.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of hypotension during anesthesia,Treatment of mild to moderate hypotension,Treatment of supraventricular tachycardia (off-label),Nasal decongestant (topical use)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion: initial rate 100-180 mcg/min, titrate to effect; maintenance 40-60 mcg/min. Concentrations: 100 mcg/m L (10 mg in 100 m L NS) or 200 mcg/m L (20 mg in 100 m L NS). Administer via central line preferred.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life: 2-3 hours; clinical context: requires repeated dosing or continuous infusion for sustained effect.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Primarily metabolized by monoamine oxidase (MAO) and sulfotransferase in the liver and gastrointestinal tract; subject to first-pass metabolism.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal (80-90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Volume of distribution: 2-4 L/kg; clinical meaning: extensive tissue distribution with limited CNS penetration.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral: <1% due to extensive first-pass metabolism; intranasal: up to 50% (variable); IM/SC: 100% bioavailable.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dose adjustment required for GFR >15 m L/min. For GFR <15 m L/min or on dialysis: use with caution; no specific dose adjustment guidelines; monitor blood pressure and adjust infusion rate accordingly due to potential reduced clearance.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh A: no adjustment. Child-Pugh B and C: consider starting at lower infusion rates (e.g., 50-100 mcg/min) and titrate carefully due to reduced clearance and increased sensitivity.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous infusion: 0.5-1 mcg/kg/min, titrate to effect; maximum 10 mcg/kg/min. Administer via central line preferred. For bolus: 0.5-1 mcg/kg every 10-15 min as needed (off-label; use with caution).
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients may have increased sensitivity; start at lower infusion rates (e.g., 50-100 mcg/min) and titrate slowly; monitor blood pressure closely due to risk of hypertension and bradycardia.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None.
None
May cause severe hypertension, bradycardia, or arrhythmias; use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis; extravasation may cause tissue necrosis.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to phenylephrine; severe hypertension; ventricular tachycardia; narrow-angle glaucoma; concurrent use with MAO inhibitors or within 14 days of MAOI therapy.
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No known food interactions with intravenous phenylephrine. Maintain usual diet unless directed otherwise by your healthcare provider.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Phenylephrine is a sympathomimetic amine used as a vasopressor. For the first trimester, there is no evidence of increased risk of major congenital malformations based on human data, although animal studies are limited. For the second and third trimesters, maternal use may reduce uteroplacental blood flow due to vasoconstriction, potentially causing fetal hypoxia and bradycardia. It is generally avoided in pregnancy unless clearly needed.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Phenylephrine is excreted into breast milk in minimal amounts, with an estimated M/P ratio of approximately 0.2. The relative infant dose is low (<1% of maternal weight-adjusted dose). Oral bioavailability is poor, making significant exposure to the infant unlikely. However, use with caution, especially in preterm infants or those with cardiovascular instability.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy may increase plasma volume and cardiac output, but phenylephrine pharmacokinetics are not significantly altered. Dose adjustments are primarily based on maternal blood pressure response. Typically, no routine dose adjustment is required, but careful titration is recommended due to potential for exaggerated hypertension or decreased placental perfusion.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Phenylephrine hydrochloride in 0.9% sodium chloride is used for the prevention and treatment of hypotension during anesthesia. Administer via IV infusion with careful titration to avoid reflex bradycardia. Monitor blood pressure continuously, especially in patients with preexisting hypertension or bradyarrhythmias. Use with caution in patients with hyperthyroidism, severe atherosclerosis, or narrow-angle glaucoma. Not recommended for patients with severe hypertension or ventricular tachycardia. In obstetrics, may decrease uterine blood flow; use only if clearly needed.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously to raise your blood pressure during surgery or medical procedures.,Inform your healthcare provider if you have high blood pressure, heart problems, thyroid disease, or glaucoma.,Tell your doctor about all medications you are taking, especially MAO inhibitors, antidepressants, or other blood pressure medications.,Report any chest pain, slow heartbeat, headache, or difficulty breathing during the infusion.,This medication is not for self-administration; it is given only in a hospital setting.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Dosulepin, a tricyclic antidepressant, inhibits the reuptake of norepinephrine, leading to increased synaptic norepinephrine concentrations. This potentiates the vasopressor effects of phenylephrine, a direct-acting alpha-1 adrenergic receptor agonist, resulting in an exaggerated hypertensive response and increased risk of cardiac arrhythmias. Clinically, this interaction can cause severe hypertension, reflex bradycardia, and potential cardiovascular complications."
"Phenylephrine, a selective α1-adrenergic receptor agonist, can potentiate the hypertensive effects of pirlindole, a monoamine oxidase inhibitor (MAOI) with non-selective MAO-A and MAO-B inhibition. This combination increases the risk of a hypertensive crisis due to excessive norepinephrine accumulation at sympathetic nerve terminals. Patients may experience severe hypertension, headache, palpitations, and potential intracranial hemorrhage."
"Phenylephrine, a selective α1-adrenergic receptor agonist, induces vasoconstriction and elevates blood pressure. Methylergometrine, an ergot alkaloid, stimulates smooth muscle contraction via serotonergic (5-HT2) and α-adrenergic receptors, primarily used to prevent postpartum hemorrhage. Concurrent use may lead to additive or synergistic vasopressor effects, resulting in severe hypertension, potential hypertensive crisis, and increased risk of cerebrovascular or cardiac events such as stroke or myocardial ischemia."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction, increasing peripheral vascular resistance and blood pressure.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is: Intravenous infusion: initial rate 100-180 mcg/min, titrate to effect; maintenance 40-60 mcg/min. Concentrations: 100 mcg/m L (10 mg in 100 m L NS) or 200 mcg/m L (20 mg in 100 m L NS). Administer via central line preferred.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is classified as Category A/B. Phenylephrine is a sympathomimetic amine used as a vasopressor. For the first trimester, there is no evidence of increased risk of major congenital malformations based on human dat. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.